Discover 203 paid clinical trials in Montana. Search by city or condition to find a research study near you that matches your needs across various therapeutic areas.
Whether youāre looking to join as a healthy volunteer in a paid clinical trial or need condition-specific options, Montana has a wide range of research opportunities to suit. Active recruitment is underway at research centers in Billings, Missoula, and Great Falls, allowing participants to access advanced treatments and high-quality medical care.
Filter
1
Filter results
Results: 203
Active & Responsive
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
for
Metastatic Dedifferentiated Liposarcoma,
Location: Boston MA, Waterford CT, Guilford CT, New Haven CT,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT06422806
Phase3, Recruiting
Active & Responsive
A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events
for
Diabetes Mellitus, Type 2, PreDiabetes, Metabolic Syndrome
Location: Boston MA, Lake Success NY, Mount Kisco NY,
Get alerts for new trials in your area by subscribing now
Active & Responsive
Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays
for
Ampulla of Vater Carcinoma, Appendix Carcinoma,
Location: The Bronx NY, Millville DE, Lewes DE, Rehoboth Beach DE,
Sponsor: Alliance for Clinical Trials in Oncology
Sex: All
Age: 18+
Code: NCT07283939
Recruiting
Active & Responsive
EASi-PROTKT⢠- A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
for
Hypothyroidism
Location: Boston MA, Dracut MA, Nashua NH, Smithtown NY,
Sponsor: AbbVie
Sex: All
Age: 18 - 70+
Code: NCT06345339
Phase2, Phase3, Recruiting
Active & Responsive
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
for
Breast Neoplasms, Breast Cancer
Location: Norfolk VA, Nashville TN, Skokie IL, Houston TX,